Read twice and referred to the Committee on Small Business and Entrepreneurship.
This bill strengthens commercialization provisions for the federal SBIR and STTR small business research programs.
It requires commercialization expertise in peer review, creates agency Technology Commercialization Officials, expands allowable technical and business assistance (including hiring staff), funds I‑Corps participation, mandates an annual commercialization impact assessment, and establishes prioritized patent examination and USPTO outreach for program recipients.
It also authorizes limited ‘‘phase flexibility’’ awards for agencies in 2025–2027 with agency-specific percentage caps and requires briefings and reports to congressional committees.
Narrow, bipartisan-friendly administrative fixes with low fiscal impact and clear implementation paths boost prospects, though interagency coordination and drafting quirks create some friction.
Relative to its intended legislative type, this bill is a substantive policy change that is generally well integrated into existing law and includes multiple specific statutory mechanisms to advance commercialization in SBIR/STTR programs. It specifies numerical limits, funding-use allowances, duties for designated officials, and concrete data elements for assessment and reporting.
Role of new agency officials: commercialization help versus added bureaucracy.
Role of new agency officials: commercialization help versus added bureaucracy.
Overall supportive: the bill directs more commercialization support, technical assistance, and IP help to small innovators.
It strengthens pathways from research to market, while adding data collection for program accountability.
Some provisions (reporting thresholds, implementation details) are unclear and may need equity safeguards.
Generally favorable as targeted, practical reforms to raise commercialization rates.
The bill contains sensible accountability and modest spending limits, but needs clarity on implementation, the odd assessment threshold, and measurable cost estimates.
Would seek defined evaluation timelines and cost controls.
Cautiously skeptical: supports improving commercialization for small businesses but wary of added bureaucracy, new official mandates, and expanded grant flexibility.
Concerns center on federal expansion, potential for mission creep, and uncertain fiscal effects.
Would prefer narrower mandates and sunset or oversight provisions.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Narrow, bipartisan-friendly administrative fixes with low fiscal impact and clear implementation paths boost prospects, though interagency coordination and drafting quirks create some friction.
The bill has not accumulated any surfaced votes yet.
Role of new agency officials: commercialization help versus added bureaucracy.
Narrow, bipartisan-friendly administrative fixes with low fiscal impact and clear implementation paths boost prospects, though interagency…
Relative to its intended legislative type, this bill is a substantive policy change that is generally well integrated into existing law and includes multiple specific statutory mechanisms to advance commercialization in…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.